Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Trimethoprim is an antifolate antibiotic often used in combination with sulfamethoxazole to treat a number of infections, including those of the urinary tract, respiratory tract, and gastrointestinal tract. Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and...
- Mechanism
- Curator reviewed · 5 references
Trimethoprim is a reversible inhibitor of dihydrofolate reductase, one of the principal enzymes catalyzing the formation of tetrahydrofolic acid (THF) from dihydrofolic acid (DHF). Tetrahydrofolic acid is necessary for the biosynthesis of bacterial nucleic acids and proteins and ultimately for continued bacterial survival - inhibiting its synthesis, then, results in bactericidal activity. Trimethoprim binds with a much stronger affinity to bacterial dihydrofolate reductase as compared to its mammalian counterpart, allowing trimethoprim to selectively interfere with bacterial biosynthetic processes.
Trimethoprim is often given in combination with sulfamethoxazole, which inhibits the preceding step in bacterial protein synthesis - given together, sulfamethoxazole and trimethoprim inhibit two consecutive steps in the biosynthesis of bacterial nucleic acids and proteins. As a monotherapy trimethoprim is considered bacteriostatic, but in combination with sulfamethoxazole is thought to exert bactericidal activity.
- Primary indication
- As a monotherapy, trimethoprim is indicated for the treatment of acute episodes of uncomplicated urinary tract infections caused by susceptible bacteria, including E. coli., K. pneumoniae, Enterobacter spp., P. mirabilis, and coagulase-negative Staphylococcus species.Curator reviewed · 18 structured indications
- Formula / weight
- C14H18N4O3 · 290.3177 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1973
- Code names
- BW 56-72 · NIH-204 · NSC-106568 · Ro 6-2153-12 F
- Brand names
- Bactrim
- Polytrim
- Primsol
- Septra
- Sulfatrim
Resolves to
IEDVJHCEMCRBQM-UHFFFAOYSA-NSMILESCOC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OCWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Trimethoprim, and which of those have an active Phase 3 trial?